Skip to content
Triveni Bio
News

The latest company updates, news, and insights

Triveni Bio Doses First Healthy Volunteers with Next-Generation Bispecific Antibody TRIV-573 Targeting Kallikreins 5 & 7 and Interleukin 13 in Phase 1 Clinical Trial

Press Release
5.18.2026

Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples

Press Release
9.23.2025

Fierce Biotech names Triveni Bio a “Fierce 15” Biotech Company of 2025

Press Release
9.22.2025
Top